Sonoma Pharmaceuticals, Inc. · NASDAQ:SNOA
Sonoma Pharmaceuticals — Investor Presentation (January 2024)
28 slides from Sonoma Pharmaceuticals's investor presentation, Jan 10, 2024
Slide 1: Sonoma Pharmaceuticals, Inc. Investor Presentation January 2024
Sonoma Pharmaceuticals, Inc. Investor Presentation January 2024
Slide 2: Legal Disclaimers
Legal Disclaimers INVESTOR PRESENTATION This communication is for informational purposes only. The information contained herein does not purport to be all - inclusive. T he data contained herein is derived from various internal and external sources. No representation is made as to the reasonableness
Slide 3: About Sonoma
Sonoma Pharmaceuticals is a global healthcare leader for developing and producing stabilized hypochlorous acid ( HOCl ) products for a wide range of applications, including dermatology, wound care, eye care, nasal care, oral care, podiatry, animal health and non - toxic disinfectants. Sonoma’s produ
Slide 4: Investment Highlights
Over 20 years of experience developing and manufacturing HOCl products, over 100 research articles, papers and clinical and case studies, over 50 active U.S. and international patents, and continual product innovation Hypochlorous Acid Industry Leader 21 U.S. FDA clearances as 510(k) medical devices
Slide 5: Sonoma's Microcyn Technology
Sonoma’s Microcyn ® Technology Patented, Stabilized Triple - Action Topical Technology • A powerful anti - microbial – reduces microbial load, including destruction of biofilms • Anti - inflammatory agent – reduces itch and pain • Anti - pruritic activity • Tissue healing (increased blood/oxygen flo
Slide 6: What is Hypochlorous Acid?
What is Hypochlorous Acid? During the activation of neutrophils, respiratory bursts generate hydrogen peroxide (H 2 O 2 ) and the activated granule enzyme myeloperoxidase converts H 2 O 2 to hypochlorous acid (HOCl) • Produced by neutrophils in the body as part of its defense mechanism • Highly acti
Slide 7: Research articles and studies on Microcyn technology
Over 100 research articles and case and clinical studies showcasing both the efficacy and safety of our Microcyn ® technology • Dermodacyn ® Disinfecting solution study on viability of SARS - CoV - 2, see https://www.sciencedirect.com/science/article/pii/S019567012030339X • Endocyn ® study on cellul
Slide 8: Cutting Edge Manufacturing
• 57,153 square foot state - of - the - art facility • ISO 9001, ISO 13485 and cGMP certified • MOH, KFDA, SFDA, KSA, TGA, EN, Biocide and numerous other national listings and approvals • Shipping to over 55 countries • Highly trained staff of 162 employees CUTTING EDGE MANUFACTURING Flexible operat
Slide 9: Manufacturing facility in Guadalajara, Mexico
Located in Guadalajara, Mexico Laboratory Packaging Area Labeling Boxing Ready for shipment Warehouse Air Systems Product Water Treatment System Materials Testing Laboratory Manufacturing Facility 9
Slide 10: Robust International Distribution Network
Robust International Distribution Network OVER 40 GLOBAL PARTNERS generating strong revenues internationally and in the U.S. • Expand presence in new markets by replicating what works in existing markets • Continue to add new distribution partners and grow existing relationships • Continue co - deve
Slide 11: Growth Strategy
Continue to introduce new high margin products Manufacturing capabilities can support significant future growth, leading to improved margins overall • Launch new applications of Sonoma’s Microcyn ® technology for consumer - focused products, including in the cosmetic market Growth Strategy • Efficie
Slide 12: New Market Opportunities
Sonoma is expanding its partnerships and product offerings in the all - natural skin care and medical spa industries. • The global natural skin care products market size was valued at $6.7 billion in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 6.6% from 2022 to 2030. 1
Slide 13: Recent Business Developments
Introduction of new products using our Microcyn ® technology • On January 5 , 2024 , Sonoma entered into an agreement with NovaBay Pharmaceuticals, Inc . for the sale and marketing of Avenova ® - branded products in the European Union, based on Sonoma’s existing eye product Ocudox ® and sold through
Slide 14: Recent Business Developments
Expanding commercialization opportunities by investing in R&D • In March 2023 , Sonoma announced new EPA claims for its Nanocyn ® Hospital - Grade Disinfectant f or effective use against MRSA , Salmonella , Norovirus , Poliovirus , and as a fungicide . Nanocyn was previously approved for use against
Slide 15: Continuously expanding our distributor network
Continuously expanding our distributor network • Entered into a distribution agreement with Daewoong Pharmaceutical Co., Ltd. , one of the largest pharmaceutical companies in South Korea, in January 2023 for the marketing and distribution of Primocyn TM Skin Solution products • Sonoma’s Microcyn ® R
Slide 16: Management
Management Amy Trombly CEO Amy Trombly is our Chief Executive Officer and also serves on our Board of Directors . She counseled public companies for over two decades in corporate and securities law and mergers and acquisitions, including as the owner and manager of Trombly Business Law, PC . In her
Slide 17: Key Financial Metrics
Key Financial Metrics * dollars in thousands Year Ended Year Ended Six Months Ended Six Months Ended March 31, 2022* March 31, 2023 * September 30, 2022 * (unaudited) September 30, 2023 * (unaudited) $12,628 $13,272 $7,314 $6,158 Total Revenues $3,993 $4,477 $3,182 $2,194 Gross Profit $9,880 $9,047
Slide 18: Revenue Metrics
Revenue Metrics Revenues by revenue source: Year Ended March 31, Six Months Ended September 30, 2022 2023 2022 2023 $ 9,010 $ 9,426 $ 4,615 $ 4,824 Human Care 3,169 2,500 1,523 1,067 Animal Care 449 1,346 1,176 266 Service and Royalty $ 12,628 $ 13,272 $ 7,314 $ 6,158 Revenues by geographic region:
Slide 19: Thank You
THANK YOU Sonoma Pharmaceuticals Inc. 5445 Conestoga Court , Suite 150 Boulder , CO 80301 United States of America Phone: 1 - (800) 759.9305 Email: busdev@sonomapharma.com Website: www.sonomapharma.com NASDAQ: SNOA
Slide 20: Appendix: Product Portfolio
APPENDIX: Product Portfolio
Slide 21: Diverse Product Portfolio United States
Diverse Product Portfolio United States Podiacyn Everyday Foot Care Microcyn Rx Skin & Wound Care Regenacyn Scar Gel Epicyn Antimicrobial Facial Cleanser Nanocyn Hospital Grade Disinfectant Levicyn Antimicrobial Dermal Spray Celacyn Scar Management Gel Rejuvacyn Skin Repair Reliefacyn Itch, Burn, Ra
Slide 22: U.S. office dispense products
U.S. office dispense products exclusively for skin care professionals • Generates highest margins for Sonoma • Focused marketing to med spas and dermatology offices, which can resell products to their clients for a substantial margin 22
Slide 23: U.S. Animal Health Care
U.S. Animal Health Care MicrocynAH ® family of advanced animal healthcare products, safe to use on pets and livestock, and perfect for hot spots, pink eye, scratches, skin rashes and ulcers, cuts, burns, post - surgical sites, irritated skin and lacerations. • Sold in national pet - store retail cha
Slide 24: EU Products
Epicyn ® Dermatology Gramaderm ® Dermatology Pediacyn ® Dermatology Mucoclyns ® Decontamination solution Microdacyn60 ® Oral Care Blocked nose or sinuses Sinudox ® Nasal care Blepharitis treatment Ocudox ® Eye lid solution Exposure to germs and pathogens Mouth and throat infections Keloid or hypertr
Slide 25: Direct-to-consumer products
Direct - to - consumer products available through Shopify, Amazon and Amazon EU U.S. Products EU Products 25
Slide 26: Middle East products
& Middle East Microdaeyn Microsafe Disinfectant & Sanitizer Microsafe
Slide 27: Latin America and Australia/New Zealand products
Gramacyn Kit for Acne Skin Latin America Epicyn Treat Scars Right from the Start Australia and New Zealand 27
Slide 28: Asia products
Singapore, Malaysia, Thailand, Indonesia Wound Care South Korea BioDerm Biodacyn60 Wound Care Hong K ong Microdacyn60 Oral Care China Microcyn The Philippines M icrodacyn MicrocynAH Asia 28
Sonoma Pharmaceuticals — Investor Presentation (January 2024) on 6ix